Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065962 · ClinicalTrials.gov registry record · Phase 3
Secretin for the Treatment of Autism
A Phase 3 study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Completed
- Registry status
- Phase 3
- Development phase
- 85
- Enrollment target
NCT00065962 is a Phase 3 study that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 85 participants.
The verdict
NCT00065962, a Phase 3 study, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 85 participants
- Enrollment target
Study Summary
Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
Interventions
- DRUG secretin, synthetic porcine
- DRUG secretin, biologically derived porcine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 1999-06 |
| Est. Completion | 2000-05 |
| Phase | Phase 3 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065962
The ClinicalTrials.gov registry entry for NCT00065962 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which secretin, synthetic porcine is the first listed.
NCT00065962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065962 about?
NCT00065962 is a clinical study titled "Secretin for the Treatment of Autism". Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
What is the current status of trial NCT00065962?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 85 participants. The study started on 1999-06. Estimated completion is 2000-05.
What interventions are being tested in trial NCT00065962?
The interventions under investigation include: secretin, synthetic porcine (DRUG), secretin, biologically derived porcine (DRUG).
Who is sponsoring clinical trial NCT00065962?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.